Johnson & Johnson announces a new public-private partnership for the development of HIV Vaccine
Janssen Vaccines & Prevention, one of the Janssen Pharmaceutical Companies, is developing the vaccine in a public-private partnership. Along with its partners, Janssen is starting new Phase 3 trial, Mosaico.
National Institutes of Health (NIH), HIV Vaccine Trials Network (HVTN), and U.S. Army Medical Research and Development Command (USAMRDC) is partnering with Janssen for the development of the vaccine.
Mosaico is a Phase 3 trial conducted in 3,800 people in North America, South America, and Europe. The trials planned to conduct in 55 locations; vaccine will be evaluated in men who have sex with men and transgender.
Mosaico is the most extensive and second efficacy study of HIV vaccine. Imbokodo is a Phase 2b trial involving 2,600 young women, and the trial is conducted across five South African countries.
Imbokodo results are expected to release in 2021, Mosaico in 2023.
The HIV-1 vaccine will be evaluated in the Mosaico Phase 3 study, AdVac is a vector platform. HIV vaccine is administered in four doses per year.